Objectives: This study aims to evaluate the reliability and clinical utility of NS3 sequencing in hepatitis C virus (HCV) 1-infected patients who were candidates to start a PI-containing regimen. Methods: NS3 protease sequencing was performed by in-house-developed HCV-1 subtype-specific protocols. Phylogenetic analysis was used to test sequencing reliability and concordance with previous genotype/subtype assignment by commercial genotyping assays. Results: Five hundred and sixty-seven HCV plasma samples with quantifiable HCV-RNA from 326 HCV-infected patients were collected between 2011 and 2014. Overall, the success rate of NS3 sequencing was 88.9%. The success rate between the two subtype protocols (HCV-1a/HCV-1b) was similarly high for samples with HCV-RNA > 3 log IU/mL (>92% success rate), while it was slightly lower for HCV-1a samples with HCV-RNA ≤ 3 log IU/mL compared with HCV-1b samples. Phylogenetic analysis confirmed the genotype/subtype given by commercial genotyping assays in 92.9% (303/326) of cases analysed. In the remaining 23 cases (7.1%), 1 was HCV-1g (previously defined as subtype 1a), 1 was HCV-4d (previously defined as genotype 1b) and 1 was HCV-1b (previously defined as genotype 2a/2c). In the other cases, NS3 sequencing precisely resolved the either previous undetermined/discordant subtype 1 or double genotype/subtype assignment by commercial genotyping assays. Resistance-associated variants (RAVs) to PI were detected in 31.0% of samples. This prevalence changed according to PI experience (17.1% in PI-naive patients versus 79.2% in boceprevir/telaprevir/simeprevir-failing patients). Among 96 patients with available virological outcome following boceprevir/telaprevir treatment, a trend of association between baseline NS3 RAVs and virological failure was observed (particularly for HCV-1a-infected patients: 3/21 failing patients versus 0/22 achieving sustained virological response; P = 0.11). Conclusions: HCV-NS3 sequencing provides reliable results and at the same time gives two clinically relevant pieces of information: A correct subtype/genotype assignment and the detection of variants that may interfere with the efficacy of PI.

HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels / V.C. Di Maio, V. Cento, D. Di Paolo, M. Aragri, F. De Leonardis, M. Tontodonati, V. Micheli, M.C. Bellocchi, F.P. Antonucci, A. Bertoli, I. Lenci, M. Milana, L. Gianserra, M. Melis, A. Di Biagio, C. Sarrecchia, L. Sarmati, S. Landonio, S. Francioso, L. Lambiase, L.A. Nicolini, S. Marenco, L. Nosotti, V. Giannelli, M. Siciliano, D. Romagnoli, A. Pellicelli, J. Vecchiet, C.F. Magni, S. Babudieri, M.S. Mura, G. Taliani, C. Mastroianni, U. Vespasiani-Gentilucci, M. Romano, F. Morisco, A. Gasbarrini, V. Vullo, S. Bruno, C. Baiguera, C. Pasquazzi, G. Tisone, A. Picciotto, M. Andreoni, G. Parruti, G. Rizzardini, M. Angelico, C.F. Perno, F. Ceccherini-Silberstein, R. Mariani, M. Paoloni, N. Iapadre, A. Grimaldi, B. Menzaghi, T. Quirino, J. Vecchiet, B. Bruzzone, A. De Maria, S. Marenco, A. Picciotto, C. Viscoli, K. Casinelli, M. Delle Monache, M. Lichtner, C. Mastroianni, A. Aghemo, S. Bruno, M. Cerrone, M. Colombo, A. D'Arminio Monforte, E. Danieli, F. Donato, G. Gubertini, S. Landonio, C.F. Magni, A. Mancon, V. Micheli, S. Monico, F. Niero, M. Puoti, G. Rizzardini, M.L. Russo, R. Alfieri, M. Gnocchi, A. Orro, L. Milanesi, E. Baldelli, M. Bertolotti, V. Borghi, C. Mussini, D. Romagnoli, G. Brancaccio, N. Caporaso, G.B. Gaeta, V. Lembo, F. Morisco, V. Calvaruso, A. Craxí, V. Di Marco, A. Mazzola, S. Petta, E. D'Amico, P. Cacciatore, A. Consorte, V. Pace Palitti, G. Parruti, A. Pieri, E. Polilli, M. Tontodonati, M. Andreoni, M. Angelico, F. Antenucci, F.P. Antonucci, M. Aragri, D. Armenia, L. Baiocchi, M. Bellocchi, E. Biliotti, M. Biolato, L. Carioti, F. Ceccherini-Silberstein, V. Cento, G. Cerasari, C. Cerva, M. Ciotti, C. D'Ambrosio, G. D'Ettorre, F. De Leonardis, A. De Sanctis, V.C. Di Maio, D. Di Paolo, S. Francioso, C. Furlan, P. Gallo, A. Gasbarrini, V. Giannelli, L. Gianserra, A. Grieco, S. Grieco, L. Lambiase, B. Lattanzi, I. Lenci, V. Malagnino, M. Manuelli, M. Merli, L. Miglioresi, M. Milana, L. Nosotti, D. Palazzo, C. Pasquazzi, A. Pellicelli, C.F. Perno, M. Romano, F. Santopaolo, M.M. Santoro, L. Sarmati, C. Sarrecchia, D. Sforza, M. Siciliano, M.C. Sorbo, M. Spaziante, V. Svicher, G. Taliani, E. Teti, G. Tisone, V. Vullo, A. Mangia, S. Babudieri, I. Maida, M. Melis, M.S. Mura, L. Falconi, D. Di Giammartino, P. Tarquini. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - 71:3(2016), pp. 739-750. [10.1093/jac/dkv403]

HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

V. Cento;C.F. Perno;B. Menzaghi;A. D'Arminio Monforte;A. Mancon;V. Micheli;S. Monico;C.F. Perno;
2016

Abstract

Objectives: This study aims to evaluate the reliability and clinical utility of NS3 sequencing in hepatitis C virus (HCV) 1-infected patients who were candidates to start a PI-containing regimen. Methods: NS3 protease sequencing was performed by in-house-developed HCV-1 subtype-specific protocols. Phylogenetic analysis was used to test sequencing reliability and concordance with previous genotype/subtype assignment by commercial genotyping assays. Results: Five hundred and sixty-seven HCV plasma samples with quantifiable HCV-RNA from 326 HCV-infected patients were collected between 2011 and 2014. Overall, the success rate of NS3 sequencing was 88.9%. The success rate between the two subtype protocols (HCV-1a/HCV-1b) was similarly high for samples with HCV-RNA > 3 log IU/mL (>92% success rate), while it was slightly lower for HCV-1a samples with HCV-RNA ≤ 3 log IU/mL compared with HCV-1b samples. Phylogenetic analysis confirmed the genotype/subtype given by commercial genotyping assays in 92.9% (303/326) of cases analysed. In the remaining 23 cases (7.1%), 1 was HCV-1g (previously defined as subtype 1a), 1 was HCV-4d (previously defined as genotype 1b) and 1 was HCV-1b (previously defined as genotype 2a/2c). In the other cases, NS3 sequencing precisely resolved the either previous undetermined/discordant subtype 1 or double genotype/subtype assignment by commercial genotyping assays. Resistance-associated variants (RAVs) to PI were detected in 31.0% of samples. This prevalence changed according to PI experience (17.1% in PI-naive patients versus 79.2% in boceprevir/telaprevir/simeprevir-failing patients). Among 96 patients with available virological outcome following boceprevir/telaprevir treatment, a trend of association between baseline NS3 RAVs and virological failure was observed (particularly for HCV-1a-infected patients: 3/21 failing patients versus 0/22 achieving sustained virological response; P = 0.11). Conclusions: HCV-NS3 sequencing provides reliable results and at the same time gives two clinically relevant pieces of information: A correct subtype/genotype assignment and the detection of variants that may interfere with the efficacy of PI.
No
English
Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; RNA, Viral; Retrospective Studies; Sequence Analysis, DNA; Viral Nonstructural Proteins; Drug Resistance, Viral; Mutation; Pharmacology; Pharmacology (medical); Infectious Diseases
Settore MED/07 - Microbiologia e Microbiologia Clinica
Articolo
Sì, ma tipo non specificato
Pubblicazione scientifica
2016
Oxford University Press
71
3
739
750
12
Pubblicato
Periodico con rilevanza internazionale
Aderisco
info:eu-repo/semantics/article
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels / V.C. Di Maio, V. Cento, D. Di Paolo, M. Aragri, F. De Leonardis, M. Tontodonati, V. Micheli, M.C. Bellocchi, F.P. Antonucci, A. Bertoli, I. Lenci, M. Milana, L. Gianserra, M. Melis, A. Di Biagio, C. Sarrecchia, L. Sarmati, S. Landonio, S. Francioso, L. Lambiase, L.A. Nicolini, S. Marenco, L. Nosotti, V. Giannelli, M. Siciliano, D. Romagnoli, A. Pellicelli, J. Vecchiet, C.F. Magni, S. Babudieri, M.S. Mura, G. Taliani, C. Mastroianni, U. Vespasiani-Gentilucci, M. Romano, F. Morisco, A. Gasbarrini, V. Vullo, S. Bruno, C. Baiguera, C. Pasquazzi, G. Tisone, A. Picciotto, M. Andreoni, G. Parruti, G. Rizzardini, M. Angelico, C.F. Perno, F. Ceccherini-Silberstein, R. Mariani, M. Paoloni, N. Iapadre, A. Grimaldi, B. Menzaghi, T. Quirino, J. Vecchiet, B. Bruzzone, A. De Maria, S. Marenco, A. Picciotto, C. Viscoli, K. Casinelli, M. Delle Monache, M. Lichtner, C. Mastroianni, A. Aghemo, S. Bruno, M. Cerrone, M. Colombo, A. D'Arminio Monforte, E. Danieli, F. Donato, G. Gubertini, S. Landonio, C.F. Magni, A. Mancon, V. Micheli, S. Monico, F. Niero, M. Puoti, G. Rizzardini, M.L. Russo, R. Alfieri, M. Gnocchi, A. Orro, L. Milanesi, E. Baldelli, M. Bertolotti, V. Borghi, C. Mussini, D. Romagnoli, G. Brancaccio, N. Caporaso, G.B. Gaeta, V. Lembo, F. Morisco, V. Calvaruso, A. Craxí, V. Di Marco, A. Mazzola, S. Petta, E. D'Amico, P. Cacciatore, A. Consorte, V. Pace Palitti, G. Parruti, A. Pieri, E. Polilli, M. Tontodonati, M. Andreoni, M. Angelico, F. Antenucci, F.P. Antonucci, M. Aragri, D. Armenia, L. Baiocchi, M. Bellocchi, E. Biliotti, M. Biolato, L. Carioti, F. Ceccherini-Silberstein, V. Cento, G. Cerasari, C. Cerva, M. Ciotti, C. D'Ambrosio, G. D'Ettorre, F. De Leonardis, A. De Sanctis, V.C. Di Maio, D. Di Paolo, S. Francioso, C. Furlan, P. Gallo, A. Gasbarrini, V. Giannelli, L. Gianserra, A. Grieco, S. Grieco, L. Lambiase, B. Lattanzi, I. Lenci, V. Malagnino, M. Manuelli, M. Merli, L. Miglioresi, M. Milana, L. Nosotti, D. Palazzo, C. Pasquazzi, A. Pellicelli, C.F. Perno, M. Romano, F. Santopaolo, M.M. Santoro, L. Sarmati, C. Sarrecchia, D. Sforza, M. Siciliano, M.C. Sorbo, M. Spaziante, V. Svicher, G. Taliani, E. Teti, G. Tisone, V. Vullo, A. Mangia, S. Babudieri, I. Maida, M. Melis, M.S. Mura, L. Falconi, D. Di Giammartino, P. Tarquini. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - 71:3(2016), pp. 739-750. [10.1093/jac/dkv403]
reserved
Prodotti della ricerca::01 - Articolo su periodico
174
262
Article (author)
no
V.C. Di Maio, V. Cento, D. Di Paolo, M. Aragri, F. De Leonardis, M. Tontodonati, V. Micheli, M.C. Bellocchi, F.P. Antonucci, A. Bertoli, I. Lenci, M. ...espandi
File in questo prodotto:
File Dimensione Formato  
dkv403.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 694.06 kB
Formato Adobe PDF
694.06 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/561049
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
social impact